AIGOM https://validator.w3.org/feed/docs/rss2.html AIGOM 2026: NOVITA’ NEL TRATTAMENTO DELLE NEOPLASIE GINECOLOGICHE, VERONA 21 APRILE 2026 HOME THE PATHOLOGIC RESPONSE EVALUATION AND DETECTION IN CIRCULATING TUMOR-DNA STUDY: ULTRASENSITIVE CIRCULATING TUMOR-DNA ASSESSMENT OF BREAST CANCER MINIMAL RESIDUAL DISEASE. THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER WITH DRIVER ALTERATIONS: ASCO LIVING GUIDELINE, 2026.3.1. 26-27-28 MARZO 2026-NEGRAR DI VALPOLICELLA (VR)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA OPPORTUNISTIC SALPINGECTOMY FOR PREVENTION OF TUBO-OVARIAN CARCINOMA: THE EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY CONSENSUS STATEMENTS. 15 GIUGNO 2026-AIGOM LE NOVITA’ DA CHICAGO 2026: L’EVOLUZIONE DELLE CONOSCENZE IN ONCOLOGIA AIGOM: 2026 CARCINOMA MAMMARIO METASTATICO: QUALI NOVITA’?-12 OTTOBRE 2026 WEBINAR 18-19 MAGGIO 2026 RIMINI-CONVEGNO GRANDANGOLO IN ONCOLOGIA ONCOVISION 2026 PREVALENCE AND REACTIVATION OF HEPATITIS B AND C IN PATIENTS UNDERGOING CHEMOTHERAPY FOR SOLID TUMORS. CONSIGLIO DIRETTIVO ERADICATION OF HELICOBACTER PYLORI IN THE PRIMARY PREVENTION OF GASTRIC CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS 22 GIUGNO 2026, PADOVA- PADUA MASTERCLASS IN NEURO-ONCOLOGY 2026 PREDICTING THE PROGNOSIS OF BREAST CANCER BY USING NUTRION-BASED INDEX: A SYSTEMATIC REVIEW AND META-ANALYSIS. FINAL ANALYSIS RESULTS AND PATIENT-REPORTED OUTCOMES FROM DESTINY-LUNG02-A DOSE-BLINDED, RANDOMIZED, PHASE 2 STUDY OF TRASTUZUMAB DERUXTECAN IN PATIENTS WITH HER2-MUTANT METASTATIC NSCLC RISK OF BREAST CANCER AFTER OVARIAN CANCER IN WOMEN WITH A PATHOGENIC/LIKELY PATHOGENIC VARIANT IN BRCA1 OR BRCA2. DEFINING CARDIOVASCULAR ENDPOINTS IN ONCOLOGY TRIALS: CHALLENGES AND OPPORTUNITIES: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION. ROMIPLOSTIM VERSUS PLACEBO FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA ADJUVANT RIBOCICLIB PLUS NONSTEROIDAL AROMATASE INHIBITOR THERAPY IN PATIENTS WITH HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER: 5-YEAR FOLLOW-UP OF NATALEE EFFICACY OUTCOMES AND UPDATED OVERALL SURVIVAL. PEMBROLIZUMAB OR PLACEBO WITH CHEMORADIOTHERAPY FOLLOWED BY PEMBROLIZUMAB OR PLACEBO FOR NEWLY DIAGNOSED, HIGH-RISK, LOCALLY ADVANCED CERVICAL CANCER (ENGOT-cx11/GOT-3047/KEYNOTE-A18): A RANDOMISED, DOUBLE-BLIND, PHASE 3 CLINICAL TRIAL. PRESENTAZIONI 21 APRILE 2026 AIGOM NOVITA’ NEL TRATTAMENTO DELLE NEOPLASIE GINECOLOGICHE 7 APRILE 2026-LUNG CANCER:WHERE WE ARE? FOURTH EDITION MELDOLA(FC) ARTICOLI SCIENTIFICI ADDITION OF CARBOPLATIN TO SEQUENTIAL TAXANE-ANTHRACYCLINE NEOADJUVANT CHEMOTHERAPY IN TRIPLE-NEGATIVE BREAST CANCER: A PHASE III RANDOMIZED CONTROLLED TRIAL. ACCMMED-SEZIONE ONCOLOGIA BOLOGNA, 12/13 MARZO 2026-CONVEGNO FOCUS SU TERAPIE INTEGRATE 2026 II EDIZIONE TEN-YEAR SURVIVAL AFTER POSTMASTECTOMY CHEST-WALL IRRADIATION IN BREAST CANCER. PRESENTAZIONI 25 FEBBRAIO 2026 TIME-OF-DAY IMMUNOCHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER: A RANDOMIZED PHASE 3 TRIAL. AIGOM-2026: GIST AVANZATI E IL VALORE DELLA GESTIONE MULTIDISCIPLINARE DEL PAZIENTE-VERONA 25 FEBBRAIO 2026 ESGO-ESTRO-ESP GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH ENDOMETRIAL CARCINOMA: UPDATE 2025. ADDRESSING COMMON MEDICATIONS THAT INFLUENCE IMMUNOTHERAPY RESPONSE IN SOLID TUMORS. PALBOCICLIB FOR HORMONE-RECEPTOR POSITIVE, HER2-POSITIVE ADVANCED BREAST CANCER. AIGOM-20/21 MARZO 2026, VERONA-PROGETTO CANOA 16° EDIZIONE-CARCINOMA MAMMARIO: QUALI NOVITA’ PER IL 2026? MANAGEMENT OF CANCER DURING PREGNANCY: ASCO GUIDELINE-2026 STRUCTURED EXERCISE AFTER ADJUVANT CHEMOTHERAPY FOR COLON CANCER. TRASTUZUMAB DERUXTECAN PLUS PERTUZUMAB FOR HER2-POSITIVE METASTATIC BREAST CANCER PREVALENCE AND ASSOCIATED FACTORS OF CHRONIC PAIN AMONG NURSES: A NATIONAL CROSS-SECTIONAL STUDY. IMMUNE CHECKPOINT INHIBITORS FOR MISMATCH REPAIR-DEFICIENT GASTROESOPHAGEAL ADENOCARCINOMA: OUTCOMES AND FEASIBILITY OF NONOPERATIVE MANAGEMENT AT MAYO CLINIC. ADJUVANT CEMIPLIMAB OR PLACEBO IN HIGH-RISK CUTANEOUS SQUAMOUS-CELL CARCINOMA. ADJUVANT EPIRUBICIN PLUS CYCLOPHOSPHAMIDE FOLLOWED BY TAXANES WITH OR WITHOUT CARBOPLATIN IN EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER (RJBC 1501): A RANDOMIZED PHASE III TRIAL. PRESENTAZIONI SCUOLA DI METODOLOGIA DELLA RICERCA 22-24 GENNAIO 2026 22-24 GENNAIO 2026-NEGRAR DI VALPOLICELLA (VR)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA PRESENTAZIONI 24 NOVEMBRE 2025 POSTMASTECTOMY RADIATION THERAPY: AN ASTRO/ASCO/SSO CLINICAL PRACTICE GUIDELINE. AIGOM 24 NOVEMBRE 2024-CARCINOMA DEL POLMONE: QUALI NOVITA’ NEL 2025? VI EDIZIONE CLINICAL CHARACTERIZATION OF FGFR2b EXPRESSION IN PATIENTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PRESENTAZIONI CANOA 20-21 MARZO 2026 NEGRAR DI VALPOLICELLA (VE)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE GIOVEDI 10 APRILE 2025 3 DICEMBRE 2025-ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE PASCALE-CANCRO E OBESITA’: UN FORTE LEGAME SPESSO “NASCOSTO” 12-13-14 FEBBRAIO 2026-NEGRAR DI VALPOLICELLA (VR)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA